Literature DB >> 14675662

Uterine papillary serous carcinomas: the exigency for clinical trials.

Karl C Podratz, Andrea Mariani.   

Abstract

Entities:  

Mesh：

Year:  2003        PMID： 14675662     DOI： 10.1016/j.ygyno.2003.10.031

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN： 0090-8258            Impact factor:   5.482


× No keyword cloud information.
  12 in total

1.  Histone deacetylase inhibitors induce apoptosis in both Type I and Type II endometrial cancer cells.

Authors:  Shujuan Jiang; Sean C Dowdy; Xue W Meng; Zhaoyu Wang; Monica B Jones; Karl C Podratz; Shi-Wen Jiang
Journal:  Gynecol Oncol       Date:  2007-02-15       Impact factor: 5.482

2.  DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo.

Authors:  Joan Tymon-Rosario; Elena Bonazzoli; Stefania Bellone; Aranzazu Manzano; Silvia Pelligra; Adele Guglielmi; Barbara Gnutti; Nupur Nagarkatti; Burak Zeybek; Paola Manara; Luca Zammataro; Justin Harold; Dennis Mauricio; Natalia Buza; Pei Hui; Gary Altwerger; Gulden Menderes; Elena Ratner; Mitchell Clark; Vaagn Andikyan; Gloria S Huang; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Alessandro D Santin
Journal:  Gynecol Oncol       Date:  2021-08-25       Impact factor: 5.304

3.  Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones.

Authors:  Dana M Roque; Stefania Bellone; Diana P English; Natalia Buza; Emiliano Cocco; Sara Gasparrini; Ileana Bortolomai; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Thomas J Rutherford; Peter E Schwartz; Alessandro D Santin
Journal:  Cancer       Date:  2013-04-12       Impact factor: 6.860

Review 4.  Promising novel therapies for the treatment of endometrial cancer.

Authors:  Paola A Gehrig; Victoria L Bae-Jump
Journal:  Gynecol Oncol       Date:  2009-11-10       Impact factor: 5.482

Review 5.  Taxanes: their impact on gynecologic malignancy.

Authors:  Carlton L Schwab; Diana P English; Dana M Roque; Alessandro D Santin
Journal:  Anticancer Drugs       Date:  2014-05       Impact factor: 2.248

6.  Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis.

Authors:  Amanda N Fader; Dana M Roque; Eric Siegel; Natalia Buza; Pei Hui; Osama Abdelghany; Setsuko Chambers; Angeles Alvarez Secord; Laura Havrilesky; David M O'Malley; Floor J Backes; Nicole Nevadunsky; Babak Edraki; Dirk Pikaart; William Lowery; Karim ElSahwi; Paul Celano; Stefania Bellone; Masoud Azodi; Babak Litkouhi; Elena Ratner; Dan-Arin Silasi; Peter E Schwartz; Alessandro D Santin
Journal:  Clin Cancer Res       Date:  2020-06-29       Impact factor: 12.531

7.  Clinicopathological and survival analysis of uterine papillary serous carcinoma: a single institutional review of 106 cases.

Authors:  Yao Wang; Mei Yu; Jia-Xin Yang; Dong-Yan Cao; Keng Shen; Jing-He Lang
Journal:  Cancer Manag Res       Date:  2018-10-25       Impact factor: 3.989

8.  Metabolomic analysis of uterine serous carcinoma with acquired resistance to paclitaxel.

Authors:  Manabu Seino; Tsuyoshi Ohta; Akiko Sugiyama; Hirotsugu Sakaki; Takeshi Sudo; Seiji Tsutsumi; Shogo Shigeta; Hideki Tokunaga; Masafumi Toyoshima; Nobuo Yaegashi; Satoru Nagase
Journal:  Oncotarget       Date:  2018-08-10

9.  HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer.

Authors:  G E Konecny; L Santos; B Winterhoff; M Hatmal; G L Keeney; A Mariani; M Jones; C Neuper; B Thomas; L Muderspach; D Riehle; H-J Wang; S Dowdy; K C Podratz; M F Press
Journal:  Br J Cancer       Date:  2008-12-16       Impact factor: 7.640

10.  Trastuzumab tolerability in the treatment of advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress HER2/neu.

Authors:  Joan Tymon-Rosario; Eric R Siegel; Stefania Bellone; Justin Harold; Naomi Adjei; Burak Zeybek; Dennis Mauricio; Gary Altwerger; Gulden Menderes; Elena Ratner; Mitchell Clark; Vaagn Andikyan; Gloria S Huang; Masoud Azodi; Peter E Schwartz; Amanda N Fader; Alessandro D Santin
Journal:  Gynecol Oncol       Date:  2021-08-06       Impact factor: 5.304
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.